Ganymede
AI NativeModern cloud platform to capture, automate, and analyze lab data.
Est 2022|Valuation $60.2M|Raised $15.2M
MarketsData Integration (ETL/ELT)
Modern cloud platform to capture, automate, and analyze lab data.
Published Aug 14, 2026
No authoritative, quantitative market share data was found in publicly accessible sources during this research.
Common patterns to validate with references:
| Starting price | Not publicly listed (likely quote-based) | Not publicly listed (contract-based; presence in marketplaces) | Typically quote-based for enterprise; public list pricing often unavailable |
| Suitable for | Teams needing programmatic instrument and application integration and a modular data layer | Organizations seeking an enterprise scientific data cloud with a broad connector ecosystem | R&D teams needing ELN and biological data modeling (strong in molecular biology) |
| Key strength | Programmatic integration approach and a focus on instrument→cloud→application data flows | Established scientific data cloud positioning and marketplace presence | Strong ELN functionality and R&D workflow support |
| Key weakness | Limited public reviews; limited public security/compliance documentation; potential roadmap risk after acquisition | Can be enterprise-heavy and may require significant services; limited public pricing | May be less focused on manufacturing/QC personas and instrument connectivity |
Ganymede and TetraScience both address instrument data capture and standardization. TetraScience has more visible marketplace presence and third-party references. Ganymede differentiates with programmatic integration concepts, though public evidence for the extent of that differentiation is limited.
Benchling is commonly selected for experimental documentation, sample tracking, and R&D workflows; Ganymede is positioned primarily as a connectivity and data infrastructure layer rather than an ELN replacement.